Investors urge science-based targets to combat superbugs

Investors managing over $13 trillion are urging global policymakers to establish science-based targets to combat antimicrobial resistance (AMR), which claims nearly 1.3 million lives annually. The initiative, backed by 80 institutions, highlights AMR's potential to incur $1 trillion in healthcare costs and 10 million deaths by 2050. The call parallels efforts to address climate change, emphasizing the need for coordinated action and data-driven strategies.